Reversibility of adverse, calcineurin-dependent cardiac remodeling

Circulation Research

Volumn 109, Issue 4, 2011, Pages 407-417

  Berry, Jeff M ^a   Le, Vien ^a   Rotter, David ^a   Battiprolu, Pavan K ^a   Grinsfelder, Bennett ^a   Tannous, Paul ^a   Burchfield, Jana S ^a   Czubryt, Michael ^b   Backs, Johannes ^b   Olson, Eric N ^b   Rothermel, Beverly A ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

heart failure; hypertrophy; remodeling

Indexed keywords

CALCINEURIN; DOXYCYCLINE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; TRANSGENE;

ANIMALS; CALCINEURIN; CARDIOMEGALY; DISEASE PROGRESSION; DOXYCYCLINE; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROMOTER REGIONS, GENETIC; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80051793072     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.228452     Document Type: Article

References (42)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322:1561-1566. (Pubitemid 20176696)
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562. (Pubitemid 26154241)
3. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the cardiovascular health study. J Am Coll Cardiol. 2004;43:2207-2215. (Pubitemid 38757586)
4. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 2005;289:H8-H16. (Pubitemid 40934076)
5. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during betablockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080.
6. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349. (Pubitemid 39491918)
7. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356. (Pubitemid 39491919)
8. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370-1380.
9. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589. (Pubitemid 38451712)
10. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228. (Pubitemid 28180855)
11. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281:1690-1693. (Pubitemid 28435588)
12. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101:2863-2869. (Pubitemid 30396019)
13. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999;5:246-247.
14. Diedrichs H, Chi M, Boelck B, Mehlhorm U, Schwinger RH. Increased regulatory activity of the calcineurin/nfat pathway in human heart failure. Eur J Heart Fail. 2004;6:3-9. (Pubitemid 38169598)
15. Diedrichs H, Hagemeister J, Chi M, Boelck B, Muller-Ehmsen J, Schneider CA. Activation of the calcineurin/nfat signalling cascade starts early in human hypertrophic myocardium. J Int Med Res. 2007;35:803-818. (Pubitemid 350238414)
16. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y. The in vivo role of p38 map kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 2001;98:12283-12288. (Pubitemid 32959865)
17. Syed F, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, Robbins J, Dorn GW 2nd. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res. 2004;95:1200-1206. (Pubitemid 39648211)
18. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y, Bolli R, Glembotski CC. Overexpression of mitogen-activated protein kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem. 2005;280:669-676. (Pubitemid 40165034)
19. Streicher JM, Ren S, Herschman H, Wang Y. Mapk-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 106:1434-1443.
20. Drazner MH. The transition from hypertrophy to failure: how certain are we? Circulation. 2005;112:936-938. (Pubitemid 41170258)
21. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600. (Pubitemid 44325350)
22. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. Fk-506-and csa-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 1992;357:692-694.
23. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol. 2002;13:121-128. (Pubitemid 35300824)
24. McCloskey DT, Turnbull L, Swigart PM, Zambon AC, Turcato S, Joho S, Grossman W, Conklin BR, Simpson PC, Baker AJ. Cardiac transgenesis with the tetracycline transactivator changes myocardial function and gene expression. Physiol Genomics. 2005;22:118-126. (Pubitemid 41356344)
25. Collins KA, Korcarz CE, Shroff SG, Bednarz JE, Fentzke RC, Lin H, Leiden JM, Lang RM. Accuracy of echocardiographic estimates of left ventricular mass in mice. Am J Physiol Heart Circ Physiol. 2001;280:H1954-H1962.
26. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, Le V, Levine B, Rothermel BA, Hill JA. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest. 2007;117:1782-1793. (Pubitemid 47036312)
27. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440-447.
28. Massare J, Berry JM, Luo X, Rob F, Johnstone JL, Shelton JM, Bassel-Duby R, Hill JA, Naseem RH. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol. 2010;21:1031-1037.
29. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins mcip1 and mcip2 in striated muscles. Circ Res. 2000;87:E61-E68.
30. Rothermel BA, Vega RB, Williams RS. The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc Med. 2003;13:15-21. (Pubitemid 36120545)
31. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Michael Ho P, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Executive summary: heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:459-463.
32. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367:356-367. (Pubitemid 43151469)
33. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-2588. (Pubitemid 41007844)
34. Dong D, Duan Y, Guo J, Roach DE, Swirp SL, Wang L, Lees-Miller JP, Sheldon RS, Molkentin JD, Duff HJ. Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of k+ channels. Cardiovasc Res. 2003;57:320-332. (Pubitemid 36144211)
35. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, Weiss RM, Kutschke W, Bassel-Duby R, Williams RS. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem. 2002;277:10251-10255. (Pubitemid 34968140)
36. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. (Pubitemid 40517094)
37. Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA, Molkentin JD. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol. 2000;32:697-709. (Pubitemid 30658937)
38. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ, Giewat M, Seidman CE, Seidman JG. An abnormal ca (2 +) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. 2000;106:1351-1359.
39. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mtor signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050-3055. (Pubitemid 38808328)
40. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A, Du XJ. Inhibition of mtor reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:1663-1670. (Pubitemid 44162470)
41. Ha T, Li Y, Gao X, McMullen JR, Shioi T, Izumo S, Kelley JL, Zhao A, Haddad GE, Williams DL, Browder IW, Kao RL, Li C. Attenuation of cardiac hypertrophy by inhibiting both mtor and nfkappab activation in vivo. Free Radic Biol Med. 2005;39:1570-1580. (Pubitemid 41642588)
42. van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. Mcip1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004;94:e18-e26.